Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Eligible patients must be at least 18 years of age with a diagnosis of multiple myeloma including elevated M-blood/urine protein or a tumor that can be evaluated by the doctor during the investigational drug's treatment.
The patient's multiple myeloma must have gotten worse during/after previous chemotherapy was given.
Any side-effects from prior chemotherapy must have subsided
Blood and urine tests must show adequate bone marrow, liver, and kidney function.
You may not be if
Any of the following will exclude patients from study participation:
indolent or smoldering myeloma or localized plasmacytoma
hyperviscosity syndrome
irradiation to 25% or more of bone marrow
prior high dose chemotherapy with bone marrow or stem cell support
current participation in other clinical trials
pregnant or breast-feeding women
known HIV-positive or AIDS-related illness
patients planning to have radiation therapy or surgery that would interrupt study therapy in the next 6 months.
Clareo Health | Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma
